載入中
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
前收盤價
US$1.42
+US$0.05 · +3.65%
盤中時間採用ET。市場資料可能有所延遲。
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
日內區間
目前US$1.42
52週區間
目前US$1.42
盤中時間採用ET。市場資料可能有所延遲。
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
日內區間
目前US$1.42
52週區間
目前US$1.42
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 140.9萬 USD | — | — | — | — |
| 毛利 | −140.9萬 USD | — | — | — | — |
| 研究與開發 | 6197.9萬 USD | 1.18億 USD | 1.03億 USD | 6271.3萬 USD | 2799.6萬 USD |
| 銷售、一般及管理費用 | 1932.8萬 USD | 2598.5萬 USD | 2358.9萬 USD | 2092.1萬 USD | 1367.1萬 USD |
| 營業費用 | 7989.8萬 USD | 1.44億 USD | 1.26億 USD | 8363.4萬 USD | 4166.7萬 USD |
| 利息收入 | 185.8萬 USD | 564.4萬 USD | 888萬 USD | 180.6萬 USD | 10萬 USD |
| 折舊和攤銷 | 140.9萬 USD | 174.8萬 USD | 151.5萬 USD | 69.1萬 USD | 24.9萬 USD |
| 營業利益 | −8130.7萬 USD | −1.44億 USD | −1.26億 USD | −8363.4萬 USD | −4166.7萬 USD |
| 淨利 | −6179.7萬 USD | −1.38億 USD | −1.17億 USD | −8182.8萬 USD | −4156.7萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$20.20
上漲空間 1322.54%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWC
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
